UCB received approval from the U.S. Food and Drug Administration (FDA) for a label extension for the company’s anti-epileptic drug, VIMPAT (lacosamide) CV, as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older.   This new approval provides clinicians with the option to prescribe VIMPAT to their pediatric patients either as an oral solution or a convenient tablet. The treatment further helps medical professionals support the U.S. pe...